The AGM is today. Purplebricks Group Plc (LON:PURP) maiden (quoted) FY16 results were reported on 16th June, ahead of our expectations: sales by 4%; P&L £1.2m better. Purplebricks is rapidly
City of London Investment Group Plc (LON:CLIG) full year results showed no surprises following the trading statement in July. Weaker markets were the dominant feature, with lower funds under management
Real Good Food Plc (LON:RGD), 2016 has been dominated by the post-disposal period following the major and successful strategic sale in May 2015 of the Napier Brown sugar business. There
PE has outperformed the stock market over most time horizons. Gresham House Strategic PLC (LON:GHS) aims to do likewise by using PE techniques to generate 15% IRR p.a. long term.
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Management has
Although Redx Pharma Plc (LON:REDX) has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the
Tissue Regenix Group Plc (LON:TRX) is now in the commercialisation phase having validated its dCELL® technology to produce ‘like-for-like’ tissue specific, structure-preserving scaffolds for use in multiple clinical settings. DermaPure
Burford Capital Limited (LON:BUR) interim results for 2016H1 produced another set of outstanding figures. The core litigation finance business was the driving force helping overall revenue grow to $76.2m, up
Avacta Group Plc (LON:AVCT) is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and
Arbuthnot Banking Group Plc (LON:ARBB) now has three legs to its business, each offering good growth options. First, the Private Bank, Arbuthnot Latham (AL) has invested heavily in staff, products
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
